WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > INC Research
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Cell and Gene Therapy
Vipergen | February 18, 2021
Vipergen ApS announced today a published study depicting a ground-breaking new medication revelation approach that empowers, interestingly, screening DNA-encoded small-molecule libraries (DELs) inside living cells. The study, published in the peer-reviewed Journal of the American Chemical Society, highlights the potential of Vipergen's Cellular Binder Trap Enrichment® (cBTE) technology to significantly grow the ability to discover novel small molecules, including against difficult-to-dru...
Eiger BioPharmaceuticals, Inc. | October 06, 2022
Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...
Industrial Impact
Chimeron Bio | January 25, 2022
Chimeron Bio, a biotechnology company pioneering a novel class of self-amplifying RNA-vaccines and therapeutics announced its plan to expand operations in the Philadelphia area and move to The Curtis, a landmark site in Center City Philadelphia under BioLabs, the leading developer and operator of life science co-working spaces in the U.S. and internationally. The move stems from Chimeron’s need for an expanded footprint to accommodate its growing R&D team and operations....
Diagnostics
Phenomix Sciences | May 27, 2022
Phenomix Sciences (Phenomix), a precision biotechnology company bringing data intelligence to the treatment of obesity, announces today the launch of its biobanking registry and outcome study. The registry will study variability in obesity by looking at patients' DNA, metabolomics, hormones, patient behavior, assessments, and treatment outcomes. The data collected will supplement the 20 billion unique data points that make up the Phenomix Sciences Obesity Platform. Mayo Clinic is the first t...
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE